Recent workplan entails how ingenuity in clinical research will be fostered in 4 years by refining basic clinical practice and giving decentralised trial rules.

Since more instances of persons suffering from lengthy COVID are coming up, WHO has asked for further research on it for better understanding and outcomes.

One-year study published in Nature Medicine, assessed brain health in 44 different disorders using anonymised health records from millions of U.S. veterans.

Sotrovimab from GSK and Vir Biotechnology and casirivimab-imdevimab from Regeneron and Roche have been taken off US market due to failure on emerging strains.